As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Thursday, Catalyst Pharmaceutical Partners ( CPRX)'s CEO ...
Nasdaq · 3y
Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its ... Even after a 11% gain to $3.32, this stock has a 52-week range of $1.29 to $3.65 and it has a market cap of $223 million. We would also note that the ...
Shares of Catalyst Pharmaceuticals, Inc. CPRX have moved up 10.1% in the past one week ... But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance ...
News: The Company announced that it is selling 14.28 million shares of its common stock in the public offering at a price ... To know more about CPRX, please visit our Company Spotlight column. -- On November 7, 2017, the Company reported third quarter ...
RTTNews · 5mon
NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. today announced that it has filed a class action lawsuit on behalf of investors who purchased the stock of Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) during the period …
Shares of Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) are down 21.69% to $1.48 on trading volume of 3.2 million shares. The company is looking to raise an addition $6 million in a stock offering on Friday. The 52-week low is 50 cents.
Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail). Catalyst Drug Positive in Second Phase III Study: Catalyst Pharmaceuticals’s CPRX shares were up 10.3% on positive top-line results from a second late-stage study on Firdapse for the ...
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CPRX at https://www.zacks.com/ap/CPRX Keywords: Catalyst Pharmaceutical, Earnings Report
Catalyst Pharmaceutical Partners (NASDAQ:CPRX - News) announced that in a direct public offering of 4 million shares of common stock and 1.2MM warrants, it will be raising $6 million in gross proceeds. The market reacted ahead of the bell driving CPRX down ...